BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 1379348)

  • 1. [Mechanism of action of the new immunosuppressants: cyclosporin A, FK 506 and rapamycin].
    Rondeau E
    Nephrologie; 1992; 13(3):137. PubMed ID: 1379348
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanisms of action of immunosuppressive agents: cyclosporin A, FK506, and rapamycin.
    Bierer BE
    Proc Assoc Am Physicians; 1995 Apr; 107(1):28-40. PubMed ID: 8630742
    [No Abstract]   [Full Text] [Related]  

  • 3. Modes of action of FK506, cyclosporin A, and rapamycin.
    Morris R
    Transplant Proc; 1994 Dec; 26(6):3272-5. PubMed ID: 7527964
    [No Abstract]   [Full Text] [Related]  

  • 4. In vivo immunopharmacology of the macrolides FK 506 and rapamycin: toward the era of rational immunosuppressive drug discovery, development, and use.
    Morris RE
    Transplant Proc; 1991 Dec; 23(6):2722-4. PubMed ID: 1721257
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of immunosuppressive drugs (CsA, FK 506, rapamycin) on the kidney microsomal cytochrome P-450 system in the rat.
    Yoshimura R; Yoshimura N; Ohmachi T; Nakatani T; Ohyama A; Miyao Y; Yamamoto K; Kishimoto T
    Transplant Proc; 1994 Oct; 26(5):2890. PubMed ID: 7524223
    [No Abstract]   [Full Text] [Related]  

  • 6. FK 506, rapamycin, and cyclosporine: effects on IL-4 and IL-10 mRNA levels in a T-helper 2 cell line.
    Wang SC; Zeevi A; Jordan ML; Simmons RL; Tweardy DJ
    Transplant Proc; 1991 Dec; 23(6):2920-2. PubMed ID: 1721312
    [No Abstract]   [Full Text] [Related]  

  • 7. FK 506 and rapamycin do not affect platelet aggregation or mitochondrial function.
    Pelekanou V; Trezise AE; Moore AL; Kay JE
    Transplant Proc; 1991 Dec; 23(6):3200-1. PubMed ID: 1721408
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative effects of rapamycin, FK 506 and cyclosporine on antibody production, lymphocyte populations and immunoglobulin isotype switching in the rat.
    Thomson AW; Propper DJ; Woo J; Whiting PH; Milton JI; Macleod AM
    Immunopharmacol Immunotoxicol; 1993 Aug; 15(4):355-69. PubMed ID: 7693791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the immunosuppressive macrolides rapamycin and FK 506 in high responder rats presensitized to major histocompatibility complex antigens.
    Propper DJ; Woo J; Macleod AM; Catto GR; Thomson AW
    Transplant Proc; 1993 Feb; 25(1 Pt 1):673-4. PubMed ID: 7679837
    [No Abstract]   [Full Text] [Related]  

  • 10. Cyclosporin A, FK506, and rapamycin: binding to immunophilins and biological action.
    Bierer BE
    Chem Immunol; 1994; 59():128-55. PubMed ID: 7524531
    [No Abstract]   [Full Text] [Related]  

  • 11. Osteoblastic differentiation is enhanced by rapamycin in rat osteoblast-like osteosarcoma (ROS 17/2.8) cells.
    Ogawa T; Tokuda M; Tomizawa K; Matsui H; Itano T; Konishi R; Nagahata S; Hatase O
    Biochem Biophys Res Commun; 1998 Aug; 249(1):226-30. PubMed ID: 9705862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia.
    Sharkey J; Butcher SP
    Nature; 1994 Sep; 371(6495):336-9. PubMed ID: 7522303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FK 506 and rapamycin: molecular probes of T-lymphocyte activation.
    Bierer BE; Jin YJ; Fruman DA; Calvo V; Burakoff SJ
    Transplant Proc; 1991 Dec; 23(6):2850-5. PubMed ID: 1721296
    [No Abstract]   [Full Text] [Related]  

  • 14. Categorizing receptor-signaling pathways with FK 506 and rapamycin.
    Hultsch T; Hohman RJ
    Transplant Proc; 1991 Dec; 23(6):2961-3. PubMed ID: 1721328
    [No Abstract]   [Full Text] [Related]  

  • 15. Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts.
    Akselband Y; Harding MW; Nelson PA
    Transplant Proc; 1991 Dec; 23(6):2833-6. PubMed ID: 1721292
    [No Abstract]   [Full Text] [Related]  

  • 16. The effects of FK 506, cyclosporine, and rapamycin on liver growth in vitro and in vivo.
    Francavilla A; Starzl TE; Carr B; Azzarone A; Carrieri G; Zeng QH; Porter KA
    Transplant Proc; 1991 Dec; 23(6):2817-20. PubMed ID: 1721287
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparative in vitro studies on the immunosuppressive activities of mycophenolic acid, bredinin, FK 506, cyclosporine, and rapamycin.
    Zeevi A; Woan M; Yao GZ; Venkataramanan R; Todo S; Starzl TE; Duquesnoy RJ
    Transplant Proc; 1991 Dec; 23(6):2928-30. PubMed ID: 1721315
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of the influence of FK 506, rapamycin, and cyclosporine on processing and presentation of particulate antigen by macrophages: assessment of a drug "carry-over" effect.
    Cooper MH; Gregory SH; Thomson AW; Fung JJ; Starzl TE; Wing EJ
    Transplant Proc; 1991 Dec; 23(6):2957-8. PubMed ID: 1721326
    [No Abstract]   [Full Text] [Related]  

  • 19. Differential inhibition of cutaneous T-cell-mediated reactions and epidermal cell proliferation by cyclosporin A, FK-506, and rapamycin.
    Duncan JI
    J Invest Dermatol; 1994 Jan; 102(1):84-8. PubMed ID: 7507155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The inhibition of T-cell-receptor-induced Fas ligand upregulation by cyclosporine and FK 506.
    Nakajima H; Oka T
    Transplant Proc; 1996 Apr; 28(2):1052-5. PubMed ID: 8623224
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.